Lexaria Bioscience Corp (OTCMKTS:LXRP) is collaborating with the US and Canada based leading labs to study the benefits of its DehydraTech delivery platform. It plans to improve the effectiveness and delivery of certain antiretroviral drugs by using its delivery platform to fight against the COVID-19 pandemic.
Researchers worldwide investigates antiretroviral drugs
Researchers from across the world are investigating antiretroviral drugs to combat coronavirus. Most of the potential drug candidates are fat-soluble. They present challenges in reaching the bloodstream of humans when administered orally. Lexaria has got expertise in the delivery of fat-soluble drugs in oral form.
According to an article published in a peer-reviewed medical journal, the patented DehydraTech delivery platform of Lexaria is proven to deliver fat-soluble drugs in human blood with increased chances of 317% quantified drug in the bloodstream within thirty minutes of administering the drug. If the delivery platform of Lexaria is capable of showing the same performance in the delivery of antiretroviral drugs, it offers an economical and effective mechanism to cure patients suffering from coronavirus.
An exploratory study in healthy volunteers
Lexaria plans to conduct the human pharmacokinetic exploratory trial in healthy volunteers on a pilot basis using three antiretroviral drugs, which are already studied on coronavirus strains. The company will compare the results with the previous outcome achieved without the use of Lexaria’s technology. It will initially conduct the study in Canada at a leading university where it has already shared the design and plan for the approval of the ethics board. Lexaria expects to provide more details after the successful completion of the study and on getting the results.
Lexaria may also conduct additional research using the patented platform for drug delivery in animal models to evaluate efficiency. The company will share its technology with the researchers worldwide for enhancing the effectiveness of drug investigations if it could achieve success in delivering antiretroviral drugs.
DehydraTech delivery platform of Lexaria is an economical solution and cutting edge technology for reduced dosage and to improve the effectiveness of ingestible drugs. It also improves the effectiveness of other beneficial molecules. DehydraTech also improves the ability of your body to quickly absorb beneficial molecules, supplements, drugs, and vitamins.
Published at Wed, 08 Apr 2020 12:36:14 +0000